These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 18590053)

  • 21. The candidate tumor suppressor BTG3 is a transcriptional target of p53 that inhibits E2F1.
    Ou YH; Chung PH; Hsu FF; Sun TP; Chang WY; Shieh SY
    EMBO J; 2007 Sep; 26(17):3968-80. PubMed ID: 17690688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of {gamma}-aminobutyric acid type A receptor-associated protein, a novel tumor suppressor, showing reduced expression in breast cancer.
    Klebig C; Seitz S; Arnold W; Deutschmann N; Pacyna-Gengelbach M; Scherneck S; Petersen I
    Cancer Res; 2005 Jan; 65(2):394-400. PubMed ID: 15695379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ATBF1 and NQO1 as candidate targets for allelic loss at chromosome arm 16q in breast cancer: absence of somatic ATBF1 mutations and no role for the C609T NQO1 polymorphism.
    Cleton-Jansen AM; van Eijk R; Lombaerts M; Schmidt MK; Van't Veer LJ; Philippo K; Zimmerman RM; Peterse JL; Smit VT; van Wezel T; Cornelisse CJ
    BMC Cancer; 2008 Apr; 8():105. PubMed ID: 18416817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Down-regulation of tumor suppressor gene FEZ1/LZTS1 in breast carcinoma involves promoter methylation and associates with metastasis.
    Chen L; Zhu Z; Sun X; Dong XY; Wei J; Gu F; Sun YL; Zhou J; Dong JT; Fu L
    Breast Cancer Res Treat; 2009 Aug; 116(3):471-8. PubMed ID: 18686028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma.
    Sathyanarayana UG; Padar A; Huang CX; Suzuki M; Shigematsu H; Bekele BN; Gazdar AF
    Clin Cancer Res; 2003 Dec; 9(17):6389-94. PubMed ID: 14695139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene.
    Cheng CW; Wu PE; Yu JC; Huang CS; Yue CT; Wu CW; Shen CY
    Oncogene; 2001 Jun; 20(29):3814-23. PubMed ID: 11439345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas.
    Toyooka KO; Toyooka S; Virmani AK; Sathyanarayana UG; Euhus DM; Gilcrease M; Minna JD; Gazdar AF
    Cancer Res; 2001 Jun; 61(11):4556-60. PubMed ID: 11389090
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.
    Lee MG; Kim HY; Byun DS; Lee SJ; Lee CH; Kim JI; Chang SG; Chi SG
    Cancer Res; 2001 Sep; 61(18):6688-92. PubMed ID: 11559536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
    Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
    Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epigenetic inactivation of Betaig-h3 gene in human cancer cells.
    Shao G; Berenguer J; Borczuk AC; Powell CA; Hei TK; Zhao Y
    Cancer Res; 2006 May; 66(9):4566-73. PubMed ID: 16651406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The roles of BTG3 expression in gastric cancer: a potential marker for carcinogenesis and a target molecule for gene therapy.
    Gou WF; Yang XF; Shen DF; Zhao S; Liu YP; Sun HZ; Takano Y; Su RJ; Luo JS; Zheng HC
    Oncotarget; 2015 Aug; 6(23):19841-67. PubMed ID: 25904053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers.
    Agathanggelou A; Dallol A; Zöchbauer-Müller S; Morrissey C; Honorio S; Hesson L; Martinsson T; Fong KM; Kuo MJ; Yuen PW; Maher ER; Minna JD; Latif F
    Oncogene; 2003 Mar; 22(10):1580-8. PubMed ID: 12629521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenetic inactivation of TSLC1 gene in nasopharyngeal carcinoma.
    Hui AB; Lo KW; Kwong J; Lam EC; Chan SY; Chow LS; Chan AS; Teo PM; Huang DP
    Mol Carcinog; 2003 Dec; 38(4):170-8. PubMed ID: 14639656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas.
    Nie Y; Yang G; Song Y; Zhao X; So C; Liao J; Wang LD; Yang CS
    Carcinogenesis; 2001 Oct; 22(10):1615-23. PubMed ID: 11577000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypermethylation leads to silencing of the SYK gene in human breast cancer.
    Yuan Y; Mendez R; Sahin A; Dai JL
    Cancer Res; 2001 Jul; 61(14):5558-61. PubMed ID: 11454707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas.
    Virmani AK; Rathi A; Sathyanarayana UG; Padar A; Huang CX; Cunnigham HT; Farinas AJ; Milchgrub S; Euhus DM; Gilcrease M; Herman J; Minna JD; Gazdar AF
    Clin Cancer Res; 2001 Jul; 7(7):1998-2004. PubMed ID: 11448917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Promoter methylation reduces C/EBPdelta (CEBPD) gene expression in the SUM-52PE human breast cancer cell line and in primary breast tumors.
    Tang D; Sivko GS; DeWille JW
    Breast Cancer Res Treat; 2006 Jan; 95(2):161-70. PubMed ID: 16322893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers.
    Sidiropoulos M; Pampalakis G; Sotiropoulou G; Katsaros D; Diamandis EP
    Tumour Biol; 2005; 26(6):324-36. PubMed ID: 16254462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
    Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
    Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequent loss of Dab2 protein and infrequent promoter hypermethylation in breast cancer.
    Bagadi SA; Prasad CP; Srivastava A; Prashad R; Gupta SD; Ralhan R
    Breast Cancer Res Treat; 2007 Sep; 104(3):277-86. PubMed ID: 17115114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.